Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New European Monographs Set ‘Robust Standards’ For Biosimilar Development

Executive Summary

A European Pharmacopoeia pilot project has resulted in the establishment of monographs for a number of complex biotherapeutics that will set “robust” standards for the development of biosimilars in the future.

You may also be interested in...



European Pharmacopoeia Moves Forward With MAb Quality Standards

A pilot project run by the European Pharmacopoeia is being expanded in an effort to produce general quality standards for monoclonal antibodies, following the adoption of a monograph for infliximab last November.

Feel The Quality: Biosimilars Dominate Standards Setting Debate In EU

The quality issues that the European Medicines Agency considers when it evaluates biosimilar medicines became clearer during a recent event held in Strasbourg, France, where delegates also learned more about the role of European Pharmacopoeia monographs in ensuring the quality of biosimilars.

Feel The Quality: Biosimilars Dominate Standards Setting Debate In EU

The quality issues that the European Medicines Agency considers when it evaluates biosimilar medicines became clearer during a recent event held in Strasbourg, France, where delegates also learned more about the role of European Pharmacopoeia monographs in ensuring the quality of biosimilars.

Related Content

Topics

UsernamePublicRestriction

Register

PS119809

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel